No Data
Yingkang Life: Report for the first quarter of 2025
INKON Life Technology (300143.SZ) released its first-quarter performance, with a net income of 29.9927 million yuan, an increase of 14.36%.
INKON Life Technology (300143.SZ) released the report for the first quarter of 2025, with the company's revenue at 4.09...
Hunan Fangsheng Pharmaceutical (603998.SH): Hunan Kexin sold 51% of its subsidiary Hospital Changsha Kexin to INKON Life Technology for 0.357 billion yuan.
On April 7th, Gelonghui reported that Hunan Fangsheng Pharmaceutical (603998.SH) announced that on April 7, 2025, Hunan Kexin held a shareholders' meeting and decided to sell 51% equity of its subsidiary hospital, Changsha Kexin, to INKON Life Technology for 0.357 billion yuan. Subsequently, depending on the completion of performance commitment targets, 29% and 20% of the equity of Changsha Kexin will be transferred respectively. Hunan Kexin plans to repurchase equity from related shareholders using the equity transfer funds obtained from the sale of Changsha Kexin's equity according to the arrangements of its shareholders' meeting and to allocate part of its non-cash assets.
Impressive Earnings May Not Tell The Whole Story For INKON Life Technology (SZSE:300143)
Yingkang Life: 2024 Annual Report Summary
Yingkang Life: 2024 Annual Report
